These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19911397)
41. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267 [TBL] [Abstract][Full Text] [Related]
42. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822 [TBL] [Abstract][Full Text] [Related]
43. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Somerville L; Cory JG Anticancer Res; 2000; 20(5B):3347-55. PubMed ID: 11131634 [TBL] [Abstract][Full Text] [Related]
44. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. Kapasi AJ; Spector DH J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543 [TBL] [Abstract][Full Text] [Related]
45. Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells. Yoon JY; Ishdorj G; Graham BA; Johnston JB; Gibson SB Apoptosis; 2014 Jan; 19(1):191-200. PubMed ID: 24057147 [TBL] [Abstract][Full Text] [Related]
46. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model. Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369 [TBL] [Abstract][Full Text] [Related]
47. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634 [TBL] [Abstract][Full Text] [Related]
48. Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin. Wilson PK; Mulligan SP; Christopherson RI Leuk Res; 2004 Jul; 28(7):725-31. PubMed ID: 15158094 [TBL] [Abstract][Full Text] [Related]
49. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. Festa M; Petrella A; Alfano S; Parente L Int J Cancer; 2009 Jun; 124(11):2728-36. PubMed ID: 19230027 [TBL] [Abstract][Full Text] [Related]
50. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346 [TBL] [Abstract][Full Text] [Related]
51. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403 [TBL] [Abstract][Full Text] [Related]
52. Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia. Rogalinska M; Goralski P; Wozniak K; Bednarek JD; Blonski JZ; Robak T; Piekarski H; Hanausek M; Walaszek Z; Kilianska ZM Leuk Res; 2009 Feb; 33(2):308-14. PubMed ID: 18676014 [TBL] [Abstract][Full Text] [Related]
53. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351 [TBL] [Abstract][Full Text] [Related]
55. Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures. Podhorecka M; Halicka HD; Klimek P; Kowal M; Dmoszynska A Leuk Res; 2009 Jul; 33(7):997-1000. PubMed ID: 18977529 [TBL] [Abstract][Full Text] [Related]
56. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. Tumilasci VF; Olière S; Nguyên TL; Shamy A; Bell J; Hiscott J J Virol; 2008 Sep; 82(17):8487-99. PubMed ID: 18579592 [TBL] [Abstract][Full Text] [Related]
57. Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. Siegmund B; Welsch J; Loher F; Meinhardt G; Emmerich B; Endres S; Eigler A Leukemia; 2001 Oct; 15(10):1564-71. PubMed ID: 11587214 [TBL] [Abstract][Full Text] [Related]
59. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation. Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551 [TBL] [Abstract][Full Text] [Related]
60. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]